In Vitro Nucleic Acid Hybridization for the Identification of High-Risk Human Papillomavirus (HPV) in Cervical Clinical Specimens

Abstract:

The reliability and specificity of the Pap smear rely on the eyewitness to perceive and an assortment of cell variations in clinically obtained cervical specimens. The improvement in early diagnosis to distinguish Human Papillomavirus (HPV) infection has been an issue. ELISA has been intended to analyze the immune response against HPV, and they can be utilized to distinguish the phase of the infection. The objective of this study to characterize the performance of In Vitro Nucleic Acid Hybridization with a correlation with Liquid-Based Cytology and HPV DNA Genotyping Test to assess its use as the potential for the identification of high-risk HPV in cervical clinical specimens. Hybridization utilizing an in vitro nucleic acid DNA-based ELISA method was performed with an improved chemiluminescent for the qualitative and semi-quantitative identification of high-risk HPV in cervical specimens. For analyzing the reliability to identify HPV DNA in cervical Pap smear, we studied the effectiveness of FDA-approved Hybrid Capture II (HCII) utilizing cervical swapping from 20 patient clinical specimens. Two scrapes-outs were positive for the occurrence of HPV. Only specimens displayed positive with HCII test were further confirmed by HPV Genotyping Test. Specimen 2 and 13 were positive for one of the 13 high-risk types in HCII test. Specimen 2 was confirmed by HPV genotyping test as a positive high-risk HPV type 58.

• Periodical: Journal of Biomimetics, Biomaterials and Biomedical Engineering (Volume 42)
• Pages: 51-58
• DOI: https://doi.org/10.4028/www.scientific.net/JBBBE.42.51
• Online since: July 2019
• Authors: Nor Azizah Parmin, Uda Hashim, Wan Azani Mustafa*, S.C.B. Gopinath, Zulida Rejali, M.N.A. Uda
• Keywords: Cervical Cancer, DNA, Human papillomavirus, Hybrid Capture II, Semi-Quantitative

References

[1] S. Zaridah, A review of cervical cancer research in Malaysia,, Med. J. Malaysia, vol. 69, no. August, p.33–41, (2014).

[2] L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-tieulent, and A. Jemal, Global Cancer Statistics, 2012,, CA a cancer J. Clin., vol. 65, no. 2, p.87–108, (2015).

DOI: 10.3322/caac.21262

[3] A. O. Zainal and I. T. Nor Saleha, National Cancer Registry Report. (2011).

[4] E. A. Mothershed and A. M. Whitney, Nucleic acid-based methods for the detection of bacterial pathogens: present and future considerations for the clinical laboratory.,, Clin. Chim. Acta., vol. 363, p.206–220, (2006).

DOI: 10.1016/j.cccn.2005.05.050

[5] P. Nieminen, S. Vuorma, M. Viikki, M. Hakama, and A. Anttila, Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer,, BJOG An Int. J. Obstet. Gynaecol., vol. 111, no. 8, p.842–848, (2004).

DOI: 10.1111/j.1471-0528.2004.00210.x

[6] H. zur Hausen, Papillomaviruses and cancer: from basic studies to clinical application.,, Nat. Rev. Cancer, vol. 2, no. 5, p.342–350, (2002).

DOI: 10.1038/nrc798

[7] J. E. Tota, M. Chevarie-Davis, L. A. Richardson, M. DeVries, and E. L. Franco, Epidemiology and burden of HPV infection and related diseases: Implications for prevention strategies,, Preventive Medicine, vol. 53. (2011).

DOI: 10.1016/j.ypmed.2011.08.017

[8] O. U. S. Preventive and S. Task, Clinical Guideline,, vol. 154, no. 5, (2011).

[9] D. Saslow, D. Solomon, H. W. Lawson, M. Killackey, S. L. Kulasingam, J. Cain, F. A. R. Garcia, A. T. Moriarty, A. G. Waxman, D. C. Wilbur, N. Wentzensen, L. S. Downs, M. Spitzer, A. B. Moscicki, E. L. Franco, M. H. Stoler, M. Schiffman, P. E. Castle, and E. R. Myers, American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer,, Am. J. Clin. Pathol., vol. 137, no. 4, p.516.

DOI: 10.1309/ajcptgd94evrsjcg

[10] S. M. Knoepp, D. L. Kuebler, and D. C. Wilbur, Correlation between Hybrid Capture II high-risk human papillomavirus DNA test chemiluminescence intensity from cervical samples with follow-up histologic results: A cytologic/histologic review of 367 cases,, Cancer Cytopathol., vol. 118, no. 4, p.209–217, (2010).

DOI: 10.1002/cncy.20093

[11] V. Bobek, K. Kolostova, D. Pinterova, G. Kacprzak, J. Adamiak, J. Kolodziej, M. Boubelik, M. Kubecova, and R. M. Hoffman, A clinically relevant, syngeneic model of spontaneous, highly metastatic B16 mouse melanoma,, Anticancer Res., vol. 30, no. 12, p.4799–4804, (2010).

[12] N. Azizah, U. Hashim, S. C. B. Gopinath, and S. Nadzirah, Gold nanoparticle mediated method for spatially resolved deposition of DNA on nano-gapped interdigitated electrodes , and its application to the detection of the human Papillomavirus,, (2016).

DOI: 10.1007/s00604-016-1954-9

[13] N. Azizah, U. Hashim, S. C. B. Gopinath, and S. Nadzirah, A direct detection of human papillomavirus 16 genomic DNA using gold nanoprobes,, Int. J. Biol. Macromol., vol. 94, p.571–575, (2017).

DOI: 10.1016/j.ijbiomac.2016.10.060

[14] S. Khunamornpong, J. Settakorn, K. Sukpan, J. Srisomboon, S. Intaraphet, and S. Siriaunkgul, High performance of combined HPV testing and genotyping for HPV16/18/52/58 in triaging women with minor cervical cytological abnormalities in northern Thailand,, J. Med. Virol., vol. 88, no. 1, p.135–143, (2016).

DOI: 10.1002/jmv.24290

[15] Qiagen, hc2 High-Risk HPV DNA Test ®,, (2008).

[16] W. Liang, J. Wang, C. Wang, Y. Lv, H. Gao, K. Zhang, H. Liu, J. Feng, L. Wang, and R. Ma, Detection of high-risk human papillomaviruses in fresh breast cancer samples using the hybrid capture 2 assay,, J. Med. Virol., vol. 85, no. 12, p.2087–2092, (2013).

DOI: 10.1002/jmv.23703

[17] E. Sala, A. Rockall, D. Rangarajan, and R. A. Kubik-Huch, The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis,, Eur J Radiol, vol. 76, no. 3, p.367–385, (2010).

DOI: 10.1016/j.ejrad.2010.01.026

[18] E. Nakayama, A. Yokoyama, H. Miyamoto, M. Igarashi, N. Kishida, K. Matsuno, A. Marzi, H. Feldmann, K. Ito, M. Saijo, and A. Takada, Enzyme-linked immunosorbent assay for detection of filovirus species-specific antibodies,, Clin. Vaccine Immunol., vol. 17, no. 11, p.1723–1728, (2010).

DOI: 10.1128/cvi.00170-10

[19] P. Halfon, D. Benmoura, A. Agostini, H. Khiri, G. Penaranda, A. Martineau, and B. Blanc, Evaluation of the clinical performance of the Abbott RealTime High-Risk HPV for carcinogenic HPV detection,, J. Clin. Virol., vol. 48, no. 4, p.246–250, (2010).

DOI: 10.1016/j.jcv.2010.05.008

[20] P. Halfon, D. Benmoura, A. Agostini, H. Khiri, A. Martineau, G. Penaranda, and B. Blanc, Relevance of HPV mRNA detection in a population of ASCUS plus women using the NucliSENS EasyQ?? HPV assay,, J. Clin. Virol., vol. 47, no. 2, p.177–181, (2010).

DOI: 10.1016/j.jcv.2009.11.011

[21] S. M. Knoepp, D. L. Kuebler, and D. C. Wilbur, Resolution of equivocal results with the Hybrid Capture II high-risk HPV DNA test: a cytologic/histologic review of 191 cases,, Diagn Mol Pathol, vol. 16, no. 3, p.125–129, (2007).

DOI: 10.1097/pdm.0b013e31805c99ae

[22] A. Mullard, 2011 FDA drug approvals,, Nat. Rev. Drug Discov., vol. 11, no. 2, p.91–94, (2012).

DOI: 10.1038/nrd3657

[23] A. Mullard, 2012 FDA drug approvals.,, Nat. Rev. Drug Discov., vol. 12, no. 2, p.87–90, (2013).

DOI: 10.1038/nrd3946

[24] B. Lowe, A. Fulbright, and I. Nazarenko, A hybrid-capture assay to detect HPV mRNA ratios in cervical specimens,, J. Virol. Methods, vol. 179, no. 1, p.142–147, (2012).

DOI: 10.1016/j.jviromet.2011.10.012

[25] M. N. Didelot, N. Boulle, A. Damay, V. Costes, and M. Segondy, Comparison of the PapilloCheck?? assay with the digene HC2 HPV DNA assay for the detection of 13 high-risk human papillomaviruses in cervical and anal scrapes,, J. Med. Virol., vol. 83, no. 8, p.1377–1382, (2011).

DOI: 10.1002/jmv.22148

[26] A. Apilux, Y. Ukita, M. Chikae, O. Chailapakul, and Y. Takamura, Development of automated paper-based devices for sequential multistep sandwich enzyme-linked immunosorbent assays using inkjet printing.,, Lab Chip, vol. 13, no. 1, p.126–35, (2013).

DOI: 10.1039/c2lc40690j

[27] C. Clavel, M. Masure, M. Levert, I. Putaud, C. Mangeonjean, M. Lorenzato, P. Nazeyrollas, R. Gabriel, C. Quereux, and P. Birembaut, Human papillomavirus detection by the hybrid capture II assay: a reliable test to select women with normal cervical smears at risk for developing cervical lesions.,, vol. 9, no. 3, p.145–150.

DOI: 10.1097/00019606-200009000-00004

[28] W. Quint, D. Jenkins, A. Molijn, L. Struijk, M. Van De Sandt, J. Doorbar, J. Mols, C. Van Hoof, K. Hardt, F. Struyf, and B. Colau, One virus, one lesion - Individual components of CIN lesions contain a specific HPV type,, J. Pathol., vol. 227, no. 1, p.62–71, (2012).

DOI: 10.1002/path.3970